Milligrams, milliliters, units: how a compounded vial gets mismeasured
A prefilled pen holds one dose and delivers it. A vial holds several, and somebody has to turn a prescription written in milligrams into a mark on a syringe printed in units. The FDA says it has received multiple reports of adverse events, some requiring hospitalization, from patients and clinicians getting that conversion wrong — and a poison control center published three cases where two of them were tenfold.
What this comes down to
- Three numbers are in play at once: the dose in milligrams, the vial's concentration in milligrams per milliliter, and the syringe's scale in units. The same figure means something different on each.
- A U-100 insulin syringe is graduated so that 100 units is one milliliter. It is not graduated in milligrams of anything, and the conversion depends entirely on the concentration of the vial in front of you.
- The FDA also reports adverse events from compounded doses beyond what the approved label holds — more per dose, more often, or escalated faster.
- PubMed holds 32 papers pairing semaglutide or tirzepatide with a dosing- or medication-error term. Insulin returns 692 through the identical filter.
The three numbers, and why they collide
The approved products removed this problem by never showing you a milliliter. A Wegovy single-dose pen is one strength, one dose, one injection; the label's escalation schedule is written entirely in milligrams per week[3]. A compounded vial puts the arithmetic back. The prescription names milligrams. The vial names milligrams per milliliter. The syringe is marked in units, and on a U-100 insulin syringe one milliliter is 100 units.
So a mark labeled 10 can be a tenth of a milliliter, and what that is worth in milligrams depends on a number printed on a different object. Change the vial's strength and the same mark delivers a different dose, with nothing on the syringe to indicate it. That's not a hypothetical variation across sellers: the roster carries vials described by the seller as a one-milligram vial and a six-milligram vial from the same company, and elsewhere a five-milligram vial and a sixty-milligram one.
Nobody here holds a medical license and this page isn't a dosing guide. The point is narrower and it's a consumer one: the conversion exists, it is done at your kitchen table, and the two facts it depends on — the concentration of your vial and what one mark on your syringe is worth — should come from the pharmacy or the prescriber that supplied them, in writing, before the first injection rather than after.
What went wrong in the published cases
A regional poison control center published three cases of adverse drug events after incorrect administration of semaglutide obtained from compounding pharmacies and an aesthetic spa. Two patients self-administered tenfold dosing errors. All three had notable nausea, vomiting and abdominal pain, with most symptoms lasting days; one sought care at a health care facility and responded to an antiemetic and intravenous fluids[1].
Two details in that paper matter more than the case count. One patient reported being dosed in milliliters and units rather than in milligrams. And one reported receiving a vial with syringes and no pharmacist counseling on how to administer the drug. The authors' own conclusion names the mechanism: vials of compounded semaglutide lack the safety features of prefilled manufactured pens and allow for large overdoses, and syringes not intended for semaglutide add the variability between milliliters, units and milligrams.
The case literature has kept growing. A 2026 case report describes angioedema after an accidental semaglutide dosing error[5], and a retrospective review of California Poison Control System data tracked how GLP-1 exposures changed as weight-management demand rose[6].
PubMed, via the E-utilities API
(semaglutide[tiab] OR tirzepatide[tiab]) AND ("dosing error*"[tiab] OR "medication error*"[tiab] OR overdose[tiab])Returned 32. Positive control — insulin, identical filter — returned 692 through the identical filter in the same session.
Insulin is the right control and not a rhetorical one: it is the other self-injected drug measured in units from a vial, it has been in homes for a century, and its error literature is twenty times the size. Thirty-two is a young literature about a problem that is not new — it is the same problem arriving in a new product category.
What the FDA says it has received
The agency's page, dated September 1, 2026, separates two failure modes[2]. The first is measurement: it reports multiple adverse events, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide, arising from patients measuring and self-administering incorrect doses and in some cases from health care professionals miscalculating doses.
The second is prescribing. The agency says it has received reports that may relate to people being prescribed compounded semaglutide or tirzepatide at doses beyond what the approved label holds — more product in a single dose, doses taken more often, or the amount increased faster than the label's titration schedule. The symptoms it lists are the familiar ones, at a volume that sent people looking for care: nausea, vomiting, diarrhea, abdominal pain and constipation. How often those show up in the trials at label doses is set out in the side-effect tables.
The FAERS analysis of 81,078 GLP-1 reports found compounded products with a preparation-error reporting odds ratio of 48.92 but dosing-error odds of 0.24 — lower, not higher[4]. That sits badly beside a poison control series of tenfold errors, and the most likely explanation is not that compounded vials are safer to measure. It is that a dosing error at home with a vial from a telehealth platform reaches a poison control center rather than a manufacturer's pharmacovigilance desk, and only one of those feeds FAERS.
How the sellers we have read describe the vial
Fourteen priced lines across four of our 242 sellers name a vial in the seller's own product label, and several name the strength in it. Ryze Rx lists a one-milligram vial and a six-milligram vial as separate products; Balanced Hormone Health lists a five-milligram semaglutide vial alongside a sixty-milligram tirzepatide one. Same drug, same syringe, wildly different arithmetic.
The picture gets denser again where a seller sells a microdose program — 23 priced lines on this roster do — because a smaller target dose means a smaller mark on the same scale. That practice has its own article.
One more clock runs alongside the arithmetic. A multi-dose vial has a beyond-use date and, per the FDA, a 28-day ceiling after first use, so the number of doses you can actually draw from it is not simply the strength divided by the dose. That is covered in storage and beyond-use dating, and what it does to the real monthly cost is what the calculator is for.
Questions people actually ask
How many units of compounded semaglutide is a milligram?
There's no general answer, and anyone who gives you one without asking about your vial is guessing. Units on an insulin syringe measure volume, not milligrams: 100 units is one milliliter. How many milligrams that milliliter holds is the vial's concentration, which differs between sellers and between products from the same seller. The conversion has to come from the pharmacy that filled it.
Why do compounded GLP-1s come in vials instead of pens?
Cost and supply. A multi-dose vial and a box of syringes is far cheaper to produce than a prefilled autoinjector, and a compounding pharmacy is not manufacturing devices. The tradeoff is the one the poison control authors named: a vial has none of the dose-limiting safety features of a prefilled pen and allows for large overdoses.
What should I ask before my first injection from a vial?
The concentration of the vial in milligrams per milliliter, what volume your prescribed dose works out to, what type of syringe the pharmacy assumed when it wrote the instructions, and the beyond-use date. Those are questions for your prescriber and the compounding pharmacy. We are not a clinical service and cannot answer them for a specific product.
Are dosing errors common with compounded GLP-1s?
Nobody can put a rate on it. The FDA says it has received multiple reports including some requiring hospitalization, and that adverse events from compounded drugs are likely underreported because state-licensed pharmacies that are not outsourcing facilities are not required to submit them. A count with no denominator is a signal to be careful, not a risk you can compare against anything.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.Administration errors of compounded semaglutide reported to a poison control center-Case series. Journal of the American Pharmacists Association, 2023. PMID 37392810 · doi:10.1016/j.japh.2023.06.017Three cases of adverse drug events after incorrect administration of compounded semaglutide, two of them tenfold dosing errors; nausea, vomiting and abdominal pain lasting days; one patient dosing in milliliters and units rather than milligrams; one receiving a vial and syringes with no pharmacist counseling; and the authors' conclusion that vials lack the safety features of prefilled manufactured pens and allow for large overdoses.
- 2.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026. Source · Document dated September 2026Multiple adverse event reports, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide from patients measuring and self-administering incorrect doses and health care professionals miscalculating doses; reports relating to doses beyond the approved label including more per dose, more frequent dosing and faster titration; and the listed symptoms of nausea, vomiting, diarrhea, abdominal pain and constipation.
- 3.WEGOVY (semaglutide) injection, solution; WEGOVY (semaglutide) tablet — prescribing information. Novo Nordisk, via the DailyMed Structured Product Labeling service, 2026. Source · Document dated June 2026The approved escalation schedule expressed entirely in milligrams per week — 0.25 mg for weeks 1 through 4, then 0.5, 1 and 1.7 mg at four-week intervals to a maintenance dose — and the single-dose presentation of the pen and syringe.
- 4.Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opinion on Drug Safety, 2026. PMID 40285721 · doi:10.1080/14740338.2025.2499670Adjusted reporting odds ratios from 81,078 GLP-1 FAERS reports: 48.92 for preparation errors and 0.24 for dosing errors in compounded products against non-compounded formulations.
- 5.Angioedema After Accidental Semaglutide Dosing Error: A Case Report. Journal of Clinical Medicine, 2026. PMID 42194666 · doi:10.3390/jcm15103705That the case literature on semaglutide dosing errors has continued to accumulate through 2026, this report describing angioedema following an accidental dosing error.
- 6.Changes in Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Exposures Following Recent Demand for Weight Management: A Retrospective Review of California Poison Control System Data. Journal of Pharmacy Technology, 2025. PMID 40371098 · doi:10.1177/87551225251332212That a state poison control system has retrospectively reviewed how GLP-1 receptor agonist exposures changed following the rise in weight-management demand. Cited for the existence and design of that review; PubMed carries no abstract for this record and nothing here is drawn from one.
Key figures